carnitine has been researched along with Ischemic Stroke in 5 studies
Ischemic Stroke: Stroke due to BRAIN ISCHEMIA resulting in interruption or reduction of blood flow to a part of the brain. When obstruction is due to a BLOOD CLOT formed within in a cerebral blood vessel it is a thrombotic stroke. When obstruction is formed elsewhere and moved to block a cerebral blood vessel (see CEREBRAL EMBOLISM) it is referred to as embolic stroke. Wake-up stroke refers to ischemic stroke occurring during sleep while cryptogenic stroke refers to ischemic stroke of unknown origin.
| Excerpt | Relevance | Reference |
|---|---|---|
| "L-carnitine has been shown to exert neuroprotective effects on cerebral ischemia, mainly by improving mitochondrial function and reducing inflammation." | 8.12 | Association Between Plasma L-Carnitine and Cognitive Impairment in Patients with Acute Ischemic Stroke. ( Bu, X; Che, B; Chen, H; He, J; Ju, Z; Peng, H; Wang, A; Xu, T; Zhang, J; Zhang, Y; Zhong, C, 2022) |
| "Higher l-carnitine levels were associated with lower risks of cardiovascular events and recurrent stroke after ischemic stroke." | 8.12 | Plasma l-carnitine and risks of cardiovascular events and recurrent stroke after ischemic stroke: A nested case-control study. ( Bao, A; Che, B; Chen, H; Du, J; He, J; Ju, Z; Lu, Z; Miao, M; Xu, T; Zhang, J; Zhang, Y; Zhong, C, 2022) |
| "Carnitine biosynthesis has been related to fatty acid oxidation, a process probably exerting neuroprotective effects." | 5.72 | Associations of plasma carnitine, lysine, trimethyllysine and glycine with incident ischemic stroke: Findings from a nested case-control study. ( Gu, S; Liu, D; Ma, Z; Wang, J; Xiao, L; Zhou, Z; Zuo, H, 2022) |
| "L-carnitine has been shown to exert neuroprotective effects on cerebral ischemia, mainly by improving mitochondrial function and reducing inflammation." | 4.12 | Association Between Plasma L-Carnitine and Cognitive Impairment in Patients with Acute Ischemic Stroke. ( Bu, X; Che, B; Chen, H; He, J; Ju, Z; Peng, H; Wang, A; Xu, T; Zhang, J; Zhang, Y; Zhong, C, 2022) |
| "Higher l-carnitine levels were associated with lower risks of cardiovascular events and recurrent stroke after ischemic stroke." | 4.12 | Plasma l-carnitine and risks of cardiovascular events and recurrent stroke after ischemic stroke: A nested case-control study. ( Bao, A; Che, B; Chen, H; Du, J; He, J; Ju, Z; Lu, Z; Miao, M; Xu, T; Zhang, J; Zhang, Y; Zhong, C, 2022) |
| "TMAO was associated with lacunar stroke but not other ischemic stroke subtypes in a model adjusted for age, sex, hypertension, diabetes, and smoking (OR, 1." | 1.91 | Trimethylamine N-Oxide and White Matter Hyperintensity Volume Among Patients With Acute Ischemic Stroke. ( Ament, Z; Bevers, MB; Bhave, VM; Couch, CA; Garcia Guarniz, AL; Irvin, MR; Kijpaisalratana, N; Kimberly, WT, 2023) |
| "Carnitine biosynthesis has been related to fatty acid oxidation, a process probably exerting neuroprotective effects." | 1.72 | Associations of plasma carnitine, lysine, trimethyllysine and glycine with incident ischemic stroke: Findings from a nested case-control study. ( Gu, S; Liu, D; Ma, Z; Wang, J; Xiao, L; Zhou, Z; Zuo, H, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 5 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Che, B | 2 |
| Chen, H | 2 |
| Wang, A | 1 |
| Peng, H | 1 |
| Bu, X | 1 |
| Zhang, J | 2 |
| Ju, Z | 2 |
| Xu, T | 2 |
| He, J | 2 |
| Zhong, C | 2 |
| Zhang, Y | 2 |
| Liu, D | 1 |
| Wang, J | 1 |
| Xiao, L | 1 |
| Gu, S | 2 |
| Ma, Z | 1 |
| Zhou, Z | 1 |
| Zuo, H | 1 |
| Du, J | 1 |
| Miao, M | 1 |
| Lu, Z | 1 |
| Bao, A | 1 |
| Kijpaisalratana, N | 1 |
| Ament, Z | 1 |
| Bevers, MB | 1 |
| Bhave, VM | 1 |
| Garcia Guarniz, AL | 1 |
| Couch, CA | 1 |
| Irvin, MR | 1 |
| Kimberly, WT | 1 |
| Yamashita, T | 1 |
| Yoshida, N | 1 |
| Emoto, T | 1 |
| Hirata, KI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Inner Mongolia Stroke Project A Randomized Controlled Trial of Immediate Blood Pressure Reduction on Death and Major Disability in Patients With Acute Ischemic Stroke in China[NCT01840072] | 4,071 participants (Actual) | Interventional | 2009-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Major disability was defined as a score of 3 to 5 on the modified Rankin Scale at 3 months after randomization. Scores on the modified Rankin Scale range from 0 to 6, with a score of 0 indicating no symptoms; a score of 5 indicating severe disability (ie, bedridden, incontinent, or requiring constant nursing care and attention); and a score of 6 indicating death (NCT01840072)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Usual Care | 502 |
| Active Antihypertensive Treatment | 500 |
Major disability was defined as a score of 3 to 5 on the modified Rankin Scale at 14 days after randomization. Scores on the modified Rankin Scale range from 0 to 6, with a score of 0 indicating no symptoms; a score of 5 indicating severe disability (ie, bedridden, incontinent, or requiring constant nursing care and attention); and a score of 6 indicating death. (NCT01840072)
Timeframe: 2 weeks
| Intervention | participants (Number) |
|---|---|
| Usual Care | 681 |
| Active Antihypertensive Treatment | 683 |
Cognitive function was measured by Montreal Cognitive Assessment at 3 months after randomization. The MoCA is a 30-item test that evaluates the following seven cognitive domains: visuospatial/executive functions, naming, memory, attention, language, abstraction, and orientation. One point is added for participants with education <12 years. Scores on the MoCA range from 0 to 30 and cognitive impairment was defined as a score of <26. (NCT01840072)
Timeframe: Three months
| Intervention | MoCA score (Median) |
|---|---|
| Usual Care | 22 |
| Active Antihypertensive Treatment | 22 |
Cognitive function was measured by the Mini-Mental State Examination at 3 months after randomization. The MMSE contains 20 items that test cognitive performance in domains including orientation, registration, attention and calculation, recall, language, and visual construction. MMSE scores were divided into three ordinal categories: 24-30 (no cognitive impairment), 19-23 (mild cognitive impairment), and 0-17 (severe cognitive impairment). (NCT01840072)
Timeframe: Three months
| Intervention | MMSE score (Median) |
|---|---|
| Usual Care | 26 |
| Active Antihypertensive Treatment | 26 |
Those patients who were still alive at hospital discharge were contacted by telephone to set up a follow-up clinical visit. Neurological function was assessed by the modified Rankin scale at the 3-month post-treatment follow-up visit. Scores on the modified Rankin Scale range from 0 to 6, with a score of 0 indicating no symptoms; a score of 5 indicating severe disability (ie, bedridden, incontinent, or requiring constant nursing care and attention); and a score of 6 indicating death. Major disability was defined as a score of 3 to 5 on the modified Rankin Scale. (NCT01840072)
Timeframe: Three months
| Intervention | Score on modified Rankin scale (Median) |
|---|---|
| Usual Care | 1.0 |
| Active Antihypertensive Treatment | 1.0 |
Those patients who are still alive at hospital discharge will be contacted by telephone to set up a follow-up clinical visit. Information on clinical deaths will be obtained. (NCT01840072)
Timeframe: 3 months
| Intervention | participants (Number) |
|---|---|
| Active Antihypertensive Treatment | 68 |
| Usual Care | 54 |
Those patients who are still alive at hospital discharge will be contacted by telephone to set up a follow-up clinical visit. Information of vascular events, such as myocardial infarction, will be collected. (NCT01840072)
Timeframe: 3 months
| Intervention | participants (Number) |
|---|---|
| Usual Care | 59 |
| Active Antihypertensive Treatment | 48 |
Those patients who are still alive at hospital discharge will be contacted by telephone to set up a follow-up clinical visit. Information of recurrent stroke will be collected. (NCT01840072)
Timeframe: 3 months
| Intervention | participants (Number) |
|---|---|
| Active Antihypertensive Treatment | 28 |
| Usual Care | 43 |
5 other studies available for carnitine and Ischemic Stroke
| Article | Year |
|---|---|
Association Between Plasma L-Carnitine and Cognitive Impairment in Patients with Acute Ischemic Stroke.
Topics: Brain Ischemia; Carnitine; Cognitive Dysfunction; Humans; Inflammation; Ischemic Stroke; Prospective | 2022 |
Associations of plasma carnitine, lysine, trimethyllysine and glycine with incident ischemic stroke: Findings from a nested case-control study.
Topics: Carnitine; Case-Control Studies; Fabaceae; Glycine; Humans; Ischemic Stroke; Lysine; Stroke; Tandem | 2022 |
Plasma l-carnitine and risks of cardiovascular events and recurrent stroke after ischemic stroke: A nested case-control study.
Topics: Aged; Biomarkers; Carnitine; Case-Control Studies; Chromatography, Liquid; Electrolytes; Female; Hum | 2022 |
Trimethylamine N-Oxide and White Matter Hyperintensity Volume Among Patients With Acute Ischemic Stroke.
Topics: Aged; Betaine; Carnitine; Cerebral Small Vessel Diseases; Choline; Cross-Sectional Studies; Female; | 2023 |
Unraveling the Effects of Trimethylamine N-Oxide on Stroke: "The lower, the better?"
Topics: Betaine; Carnitine; Cholesterol; Choline; Diet Therapy; Gastrointestinal Microbiome; Humans; Ischemi | 2021 |